A Phase 2 interventional study of glycopyrrolate, 1.0% and glycopyrrolate, 2.0% in Hyperhidrosis, sponsored by Journey Medical Corporation. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-25.
Sponsored by Journey Medical Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Hyperhidrosis with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Hyperhidrosis · United States.
Among the 55 studies in Hyperhidrosis with a site in United States, this one is the 8th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2013, is one of 16 in phase 2, and was the 19th registered.
111 studies on the registry are indexed under Hyperhidrosis; 10 are open to participants now.
Browse Hyperhidrosis studies →3 of the 55 studies in Hyperhidrosis with a site in United States are open now. Recruiting first, the newest first:
Miller Biosciences LLC · Sites in United States
Ages 18+
InMode MD Ltd. · Sites in United States, Israel
Ages 18+ · Healthy volunteers
University of Massachusetts, Worcester · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Hyperhidrosis studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 17 · Phase 3 7 · Phase 4 4
First in 1999; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is above the median of 50 across 99 interventional studies indexed under Hyperhidrosis.
Median enrollment 52 across the 51 interventional studies, 28 across the 3 observational. Of the 50 that completed or were terminated, 28 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 55 have an industry lead sponsor. The 10 most frequent:
Journey Medical Corporation is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Journey Medical Corporation has 6 studies filed under Hyperhidrosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 55 studies in Hyperhidrosis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of glycopyrrolate compared to vehicle for the treatment of axillary hyperhidrosis.
This is a randomized, vehicle controlled, dose-ranging study enrolling subjects with axillary hyperhidrosis and designed to assess the safety and efficacy of four doses of glycopyrrolate compared to vehicle. There are 5 arms in this study.
Efficacy will be assessed through the Hyperhidrosis Disease Severity Score (HDSS), Dermatology Life Quality Index (DLQI) and a gravimetric assessment of sweat production.
Safety will be assessed, at specified times during the study, through adverse events, local skin responses, serum chemistry and hematology laboratory testing, ECGs, physical examination and vital signs.
PK samples will be taken from 20 to 30 subjects participating in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
glycopyrrolate Topical Wipes, 1.0%
Drug: glycopyrrolate, 1.0%
glycopyrrolate Topical Wipes, 2.0%
Drug: glycopyrrolate, 2.0%
glycopyrrolate Topical Wipes, 3.0%
Drug: glycopyrrolate, 3.0%
glycopyrrolate Topical Wipes, 4.0%
Drug: glycopyrrolate, 4.0%
Vehicle Topical Wipes
Other: Vehicle
glycopyrrolate Topical Wipes, 1.0%
Also known as: DRM04B
glycopyrrolate Topical Wipes, 2.0%
Also known as: DRM04B
glycopyrrolate Topical Wipes, 3.0%
Also known as: DRM04B
glycopyrrolate Topical Wipes, 4.0%
Also known as: DRM04B
Vehicle Topical Wipes
Also known as: Placebo
Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4
HDSS is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities. 1 (Best), 2, 3, 4 (Worst)
Time frame: Baseline - Week 4
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4
Subjects are acclimated to the environment for 30 minutes. Dry gauze is weighed. The dry gauze is then applied to the subject's axilla with the arm down by the subject's side or on their lap during the 5-minute period of sweat production. The gauze with the sweat is then weighed. The difference between the Weight of the gauze with sweat and the dry gauze is the gravimetric sweat measurement in mg/5min.
Time frame: Baseline - Week 4
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4
Time frame: Baseline - Week 4
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6
Time frame: Baseline - Week 6
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6
Time frame: Baseline - Week 6
Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 4
The DLQI is a ten question questionnaire, used to measure the impact of skin disease on the quality of life of an affected person. The scoring of each question is as follows: Very much (3), A lot (2), A little (1), Not at all (0), Not relevant (0). Is calculated by summing the score of each question resulting in a max of 30 and a min of 0. Higher the score the more Quality of life is impaired.
Time frame: Baseline - Week 4
| Milestone | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Started | 38 | 40 | 40 | 40 | 40 |
| Completed | 34 | 36 | 39 | 30 | 39 |
| Not completed | 4 | 4 | 1 | 10 | 1 |
HDSS is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities. 1 (Best), 2, 3, 4 (Worst)
| Participants | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 | 14 | 20 | 21 | 18 | 9 |
Subjects are acclimated to the environment for 30 minutes. Dry gauze is weighed. The dry gauze is then applied to the subject's axilla with the arm down by the subject's side or on their lap during the 5-minute period of sweat production. The gauze with the sweat is then weighed. The difference between the Weight of the gauze with sweat and the dry gauze is the gravimetric sweat measurement in mg/5min.
| mg/5 min | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4 | -56.63 ± 75.02 | -67.17 ± 61.26 | -91.39 ± 71.27 | -88.40 ± 103.85 | -55.80 ± 80.65 |
| Participants | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4 | 27 | 30 | 35 | 25 | 28 |
| mg/5 min | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6 | -32.08 ± 68.55 | -51.36 ± 52.30 | -72.23 ± 64.21 | -57.15 ± 165.66 | -55.14 ± 56.92 |
| Participants | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6 | 24 | 27 | 29 | 23 | 25 |
The DLQI is a ten question questionnaire, used to measure the impact of skin disease on the quality of life of an affected person. The scoring of each question is as follows: Very much (3), A lot (2), A little (1), Not at all (0), Not relevant (0). Is calculated by summing the score of each question resulting in a max of 30 and a min of 0. Higher the score the more Quality of life is impaired.
| scores on a scale | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 4 | -6.2 ± 6.0 | -6.6 ± 4.9 | -7.0 ± 5.1 | -5.9 ± 4.7 | -3.8 ± 4.6 |
Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glycopyrrolate, 1.0% | 0/36 (0%) | 0/36 (0%) | 9/36 (25%) |
| Glycopyrrolate, 2.0% | 0/39 (0%) | 0/39 (0%) | 17/39 (43.6%) |
| Glycopyrrolate, 3.0% | 0/40 (0%) | 1/40 (2.5%) | 18/40 (45%) |
| Glycopyrrolate, 4.0% | 0/40 (0%) | 0/40 (0%) | 23/40 (57.5%) |
| Vehicle | 0/39 (0%) | 0/39 (0%) | 10/39 (25.6%) |
| Event | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/36 | 0/39 | 1/40 | 0/40 | 0/39 |
| Event | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle |
|---|---|---|---|---|---|
| Dry MouthGastrointestinal disorders | 5/36 | 9/39 | 14/40 | 15/40 | 5/39 |
| NasopharyngitisInfections and infestations | 0/36 | 4/39 | 2/40 | 2/40 | 2/39 |
| Vision blurredEye disorders | 0/36 | 2/39 | 1/40 | 4/40 | 0/39 |
| Upper respiratory tract infectionInfections and infestations | 2/36 | 1/39 | 3/40 | 1/40 | 3/39 |
| DysuriaRenal and urinary disorders | 0/36 | 0/39 | 1/40 | 3/40 | 0/39 |
| Urinary retentionRenal and urinary disorders | 0/36 | 1/39 | 0/40 | 3/40 | 0/39 |
| Dry skinSkin and subcutaneous tissue disorders | 0/36 | 2/39 | 3/40 | 2/40 | 0/39 |
| MydriasisEye disorders | 2/36 | 1/39 | 0/40 | 1/40 | 0/39 |
| SinusitisInfections and infestations | 0/36 | 0/39 | 0/40 | 1/40 | 2/39 |
| Nasal drynessRespiratory, thoracic and mediastinal disorders | 0/36 | 2/39 | 1/40 | 2/40 | 0/39 |
| Age, Categorical(Participants) | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle | Total |
|---|---|---|---|---|---|---|
| <=18 years | 2 | 2 | 0 | 1 | 0 | 5 |
| Between 18 and 65 years | 36 | 36 | 40 | 39 | 38 | 189 |
| >=65 years | 0 | 2 | 0 | 0 | 2 | 4 |
| Sex: Female, Male(Participants) | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle | Total |
|---|---|---|---|---|---|---|
| Female | 16 | 21 | 17 | 23 | 21 | 98 |
| Male | 22 | 19 | 23 | 17 | 19 | 100 |
| Ethnicity (NIH/OMB)(Participants) | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 8 | 3 | 2 | 4 | 21 |
| Not Hispanic or Latino | 34 | 32 | 37 | 38 | 36 | 177 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Glycopyrrolate, 1.0% | Glycopyrrolate, 2.0% | Glycopyrrolate, 3.0% | Glycopyrrolate, 4.0% | Vehicle | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 1 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 2 | 3 | 3 | 16 |
| White | 34 | 34 | 34 | 30 | 37 | 169 |
| More than one race | 0 | 1 | 2 | 6 | 0 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Nov 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 4 years after primary completion. A results delay was requested in Oct 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Journey Medical Corporation